



NAVANA PHARMACEUTICALS LIMITED

Corporate Office : House # 99, Road #04, Block # B,
Banani, Dhaka-1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of **Navana Pharmaceuticals Limited** and stakeholders that the Board of Directors of the company in its 31st meeting held on Sunday, 22nd October, 2023 ended at 4.00 p.m at its Corporate office at House 99, Road 4, Block #B, Banani Dhaka-1213, has considered and approved, among others, the audited Financial Statement for the year ended on June 30,2023 and took the following Price Sensitive Decisions:-

- Recommended to Name Change : To Comply with the Section 11(ka) of the Companies Act 1994 (2nd Amendment), the registered name of the company to be "**Navana Pharmaceuticals PLC**" in place of "**Navana Pharmaceuticals Limited**" subject to the approval from the regulatory authorities.
- Recommended Dividend : 13% Cash.
- Record Date : Sunday, November 19, 2023
- Date of 37th Annual General Meeting(AGM) : December 28, 2023
- Time of 37th AGM : 04.00. P.M.
- Venue of The AGM : AGM Will be held virtually using the Digital platform. Web link for joining the AGM will be communicated in due course through AGM Notice as well as Annual Report.

The Key Comparative Financial disclosure on Audited financial Statement for the year ended on June 30, 2023:

Sl.No	Particulars	2022-2023	2021-2022
I	Earnings per Share (EPS)(TK.)	3.59	3.42
ii	Net Asset Value (TK. In million)	4,372.45	3,483.05
iii	Net Asset Value per Share (NAV) (TK.)	40.71	43.41
iv	Net Operating Cash Flow Per Share (NOCFPS) (TK.)	1.80	2.48

Explanatory notes for the significant variation in the Financial Statements for the year ended June 30,2023:

Issue-1:Net Assets Value (NAV) per Share:

Due to an increase in the Number of ordinary shares of the company for the Initial public offerings (IPO) in comparison to the last year, the NAV per Share has decreased though the Net Asset Value increased.

Issue-2: Net Operating Cash Flow per Share (NOCFPS):

Net Operating Cash Flow per Share (NOCFPS) has decreased to Tk.1.80 from Tk.2.48 due to an increase of paid-up share explained above.

Notes :

- The shareholders whose name will appear in the Depository Register (CDBL) or register of the member of the company on the "**Record Date**" i.e. **19 November 2023** will be entitled to attend in the Annual General Meeting and to receive the dividend.
- Members are requested to update their Bank Account Number, Taxpayer's Identification Numbers (e-TIN), Address, E-mail address and cell no be for ether ecorddate to their respective depository participant.
- The concerned brokerage houses & merchant bankers are requested to provide us with a statement with the details (shareholders name, BOID number, e-TIN number, gross dividend receivable, applicable tax rate, and net dividend receivable) of their margin loan holders who hold shares of the Company as on the Record Date, along with the name of the contact person in this connection. The brokerage houses & merchant bankers are also requested to provide us with their Bank Account Name, Number, Routing number etc. on or before **10 December 2023**.
- In compliance with Listing Regulation 2015 of Dhaka Stock Exchange Limited and Chittagong Stock Exchange limited, the company will publish the details Annual Audited Financial Statement in its website (**www.navanapharma.com**).

Dated: October 22, 2023

By order of the Board
Sd/-
Joynul Abedin ACS
Company Secretary